HUMAN CARCINOGENS

Identified by the IARC Monographs Program

The International Agency for Research on Cancer (IARC) Monographs (www.monographs.iarc.fr) identify environmental and occupational causes of human cancer. Sometimes called the WHO "Encyclopedia of Carcinogens," the IARC Monographs are critical reviews and evaluations of the weight of the evidence that an agent can increase the risk of cancer in humans. Since the program's inception in 1971, over 1000 agents have been evaluated, including individual chemicals, complex mixtures, physical agents, biological agents, personal habits, and occupational exposures.

The agents are classified as "carcinogenic to humans" (Group 1), "probably carcinogenic to humans" (Group 2A), "possibly carcinogenic to humans" (Group 2B), "not classifiable as to their carcinogenicity to humans" (Group 3), or as "probably not carcinogenic to humans" (Group 4). This classification, based on all published scientific literature, reflects the strength of the evidence derived from epidemiological studies in humans, cancer bioassays in experimental animals, and in-vivo and in-vitro studies on the mechanisms of carcinogenicity. Evidence from studies in humans and animals is considered to be sufficient, limited, inadequate, or suggesting lack of carcinogenicity. Data from mechanistic studies are considered as providing strong, moderate, or weak evidence for a given mechanism. To date, 120 agents have been classified in Group 1, the vast majority on the basis of sufficient evidence from epidemiological studies that the agent can cause cancer at one or several sites in humans. Some important risk factors known to cause cancer in humans have however not been covered in the IARC Monographs

HAZARD VS. RISK

The classification indicates the strength of the evidence that a substance or agent causes cancer. The Monographs Programme seeks to identify cancer hazards. An agent is considered a cancer hazard if it is capable of causing cancer under some circumstances. However, it does not indicate

the level of risk associated with exposure. The cancer risk associated with substances or agents assigned the same classification may be very different, depending on factors such as the type and extent of exposure and the strength of the effect of the agent

program, notably genetic traits, reproductive status, and some nutritional factors. Other factors, such as weight control or physical activity, have been evaluated by the IARC Handbooks for their preventive effects.

The main figure shows, for each organ or group of organs in the human body, which agent(s) can cause an increased risk of cancer at a given site. FIGURE 9.1 Over 40 agents have more than one target organ site, with up to 17 sites for tobacco smoking and 14 sites for X-radiation and gamma-radiation. FIGURE 9.2 Some agents have been classified in Group 1 with less than sufficient evidence from epidemiological studies, often on the basis of sufficient evidence of carcinogenicity in experimental animals and strong evidence in exposed humans that the agent acts through a relevant mechanism of carcinogenicity. It is noteworthy that a few agents have been shown to cause cancer in the offspring of the person exposed.

FIGURE 9.1

Group 1 carcinogenic agents by target site




FIGURE 9.2 Carcinogenic agents associated with five or more cancer sites as listed here Human immunodeficiency virus type 1 Alcoholic beverages Human papillomavirus type 16 X-radiation, gamma-radiation Tobacco smoking **17** 5 14

CANCERATLAS.CANCER.ORG

2		⁶ Hematopoietic System
9	7	⁷ Skin
		⁸ Bone
	1.0	⁹ Breast
	11 12	¹⁰ Digestive Systen
Multiple Sites (Partly Unspecified)	Cyclosporine Fission products, including Strontium-90 • X-radiation, gamma-radiation (exposure in utero)	
All Cancers Combined	2,3,7,8-Tetrachlorodibenzo- para-dioxin	¹¹ Urinary System
Endothelium (Kaposi Sarcoma)	HIV type 1. • Kaposi sarcoma herpes virus	
Less Than Sufficient Evidence in Humans*	N'-Nitrosonornicotine, (NNN) and 4-(N-nitro-methyl-amino-1-(3- pyridyl)-1-but none (NNK)	
Areca nut Aristolochic Acid	2,3,4,5,8-Pentachlorodibenzofuran 3,4,5,3',4'-Pentachlorobiphenyl (PCB-126)	
Benzidine, dyes metabolized to Benzo[a]pyrene Ethanol in alcoholic beverages	Polychlorinated biphenyls dioxin like, with a Toxic Equivalent Factor according to WHO (PCBs 77, 81, 105, 114, 118, 123, 126, 156, 167, 169, 189)	¹² Genital System
Ethylene oxide Etoposide	Radionuclides, alpha-particle emitting, internally deposited	
lonizing radiation (all types) 4,4'-Methylenebis (1-chloroani-	Radionuclides, beta-particle emitting, internally deposited	

Μu (Pa

ΑI Co

En (Ka

Neutron radiation

	⁶ Hematopoietic System
	⁷ Skin
7	
	* Bone
	Bone
	⁹ Breast
	¹⁰ Digestive System
_	

Ultraviolet radiation

*Mechanistic upgrades to Group 1

Azathioprine Benzene Busulfan 1.3-Butadiene Chlorambucil Cyclophosphamide Cyclosporine Epstein-Barr virus Etoposide with cisplatin and Fission products, including Strontium-90 MELANOMA Solar radiation Polychlorinated biphenyls Ultraviolet-emitting tanning devices

Plutonium

Alcoholic beverages

Diethylstilbestrol

Helicobacter pylori Hepatitis C virus HIV type 1 Human T-cell lymphotropic virus Kaposi sarcoma herpes virus Lindane Melphalan MOPP (vincristine-prednisone-

nitrogen mustard-procarbazine

Formaldehyde

mixture)

Cyclosporine

Rubber production industry Semustine [1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1 nitrosourea, or methyl-CCNU1 Thiotepa Thorium-232 and its decay products

Pentachlorophenol

Phosphorus-32, as phosphate

 Tobacco smoking Treosulfan

Methoxsalen plus ultraviolet A

Mineral oils, untreated or mildly

X-radiation, gamma-radiation

OTHER MALIGNANT NEOPLASMS Arsenic and inorganic arsenic compounds Azathioprine Coal-tar distillation Coal-tar pitch

Shale oils Solar radiation Soot X-radiation, gamma-radiation

treated

Radium-226 and its decay products X-radiation, gamma-radiation

Estrogen-progestogen contraceptives Estrogen-progestogen

LIVER (ANGIOSARCOMA)

LIVER (HEPATOCELLULAR

menopausal therapy

Vinyl chloride

CARCINOMA)

Aflatoxins

Radium-228 and its decay products

X-radiation, gamma-radiation

ESOPHAGUS

Acetaldehyde associated with consumption of alcoholic beverages

Radium-224 and its decay products

Alcoholic beverages Betel guid with tobacco Betel quid without tobacco Smokeless tobacco

Tobacco smoking

• X-radiation, gamma-radiation **UPPER AERODIGESTIVE TRACT**

Acetaldehyde associated with

consumption of alcoholic beverages STOMACH

Helicobacter pylori Rubber production industry

 Tobacco smoking • X-radiation, gamma-radiation

KIDNEY

Tobacco smoking

Trichloroethylene

 Alcoholic beverages Estrogen-progestogen contraceptives

Hepatitis B virus Hepatitis C virus Plutonium

Thorium-232 and its decay products . Tobacco smoking (in smokers and in smokers' children)

GALLBLADDER

Thorium-232 and its decay

BILIARY TRACT

Chlonorchis sinensis 1,2-Dichloropropane Opisthorchis viverrini

PANCREAS

Smokeless tobacco Tobacco smoking

COLON AND RECTUM

Alcoholic beverages

Processed meat (consumption of)

Rubber production industry

Schistosoma haematobium

X-radiation, gamma-radiation

Aristolochic acid, plants containing

Phenacetin, analgesic mixtures

Tobacco smoking

ortho-Toluidine

URETER

Phenacetin

 Tobacco smoking X-radiation, gamma-radiation

ANUS

HIV type 1

Human papillomavirus type 16

URINARY BLADDER

Aluminum production 4-Aminobiphenyl

X-radiation, gamma-radiation

RENAL PELVIS Aristolochic acid, plants containing

Phenacetin Phenacetin, analgesic mixtures containing

Tobacco smoking

UTERINE CERVIX

contraceptives

52, 56, 58, 59

Tobacco smoking

HIV type 1

Estrogen-progestogen

Diethylstilbestrol (exposure in utero)

Human papillomavirus type 16, 18, 31, 33, 35, 39, 45, 51,

Arsenic and inorganic arsenic compounds

products

Auramine production

Benzidine Chlornaphazine Cyclophosphamide

ENDOMETRIUM

Tamoxifen

OVARY

Estrogen-progestoger

Asbestos (all forms)

Estrogen menopausal therapy

Magenta production 2-Naphthylamine

 Tobacco smoking Painter (occupational exposure as

Tobacco smoking

Estrogen menopausal therapy

Diethylstilbestrol (exposure in utero)

 Human papillomavirus type 16 VULVA

Human papillomavirus type 16

COPYRIGHT © 2019 THE AMERICAN CANCER SOCIETY, INC.

Human papillomavirus type 16

CANCERATLAS.CANCER.ORG